Interleukin-6 receptor

Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT

Retrieved on: 
Tuesday, April 27, 2021

b"Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.

Key Points: 
  • b"Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
  • In addition to Milciclib, the Company is also developing Foralumab for liver diseases.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.\n"

Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

Retrieved on: 
Tuesday, March 30, 2021

This patient will be treated under an Individual Patient Expanded Access IND.

Key Points: 
  • This patient will be treated under an Individual Patient Expanded Access IND.
  • The treatment is planned to start in the second quarter of 2021, and will continue for six months.
  • Investigators at BWH will follow this patient with detailed routine safety, neurological, imaging and PET studies to evaluate microglial imaging.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

Retrieved on: 
Tuesday, March 30, 2021

A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.

Key Points: 
  • A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated.
  • Tiziana now plans a phase 2 randomized, placebo-controlled trial in Brazil for moderate to severe hospitalized Covid-19 patients to test the drug in a more compromised group of patients.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil

Retrieved on: 
Tuesday, February 2, 2021

Data on pharmacokinetics of nasally administered Foralumab, immunological biomarkers, stimulation of Tregs and anti-drug antibody (ADA) is expected to be reported in a few weeks.

Key Points: 
  • Data on pharmacokinetics of nasally administered Foralumab, immunological biomarkers, stimulation of Tregs and anti-drug antibody (ADA) is expected to be reported in a few weeks.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT

Retrieved on: 
Wednesday, January 20, 2021

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.

Key Points: 
  • Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
  • In addition to Milciclib, the Company is also developing Foralumab for liver diseases.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

Retrieved on: 
Monday, January 4, 2021

Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.

Key Points: 
  • Furthermore, nasal anti-CD3 dampens cytotoxic CD8 T cell responses that are known to cause lung damage in COVID-19 patients.
  • Dr Thais Moreira, the lead scientist and coordinator of the clinical trial, stated:
    We are delighted to receive positive feedback from patients treated in the clinical trial.
  • This study had three cohorts: control (n=16), nasally administered Foralumab (n=12), and nasally administered Foralumab with 3 days of priming with orally administered 6 mg dexamethasone (n=11).
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET

Retrieved on: 
Tuesday, December 1, 2020

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.

Key Points: 
  • Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
  • In addition to Milciclib, the Company is also developing Foralumab for liver diseases.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Life Sciences plc: Publication of Research Note

Retrieved on: 
Monday, September 21, 2020

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Companys website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-...

Key Points: 
  • LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Companys website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-...
    Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases.
  • In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohns Disease and nasally administered foralumab for progressive multiple sclerosis.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

Retrieved on: 
Thursday, September 17, 2020

Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.

Key Points: 
  • Thus, we believe the clinical strategy with nasal administration of Foralumab either alone or in combination with dexamethasone to treat COVID-19 patients is highly innovative and scientifically very sound.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

Retrieved on: 
Tuesday, August 4, 2020

This company has conducted several recent trials in COVID-19 patients and has a large network of clinical sites throughout the US and abroad to expedite clinical trials with COVID-19 patients.

Key Points: 
  • This company has conducted several recent trials in COVID-19 patients and has a large network of clinical sites throughout the US and abroad to expedite clinical trials with COVID-19 patients.
  • Tiziana worked with Sciarra Labs to establish clinical supply of nasal sprays of Foralumab used in the recently completed Phase 1.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
  • The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.